MediGene AG (ETR:MDG1) has been given a €12.00 ($14.12) target price by Oddo Securities in a report released on Tuesday, August 8th. The firm currently has a “buy” rating on the stock.
Other equities analysts have also issued research reports about the company. Baader Bank set a €19.00 ($22.35) target price on MediGene AG and gave the company a “buy” rating in a report on Saturday, May 20th. Independent Research GmbH set a €12.00 ($14.12) price objective on MediGene AG and gave the stock a “neutral” rating in a report on Monday, May 29th.
Shares of MediGene AG (ETR:MDG1) traded up 1.33% on Tuesday, reaching €9.12. The company had a trading volume of 15,959 shares. The firm’s market capitalization is €201.72 million. MediGene AG has a 12 month low of €6.65 and a 12 month high of €15.19. The firm’s 50 day moving average is €10.37 and its 200 day moving average is €11.48.
About MediGene AG
Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors.
What are top analysts saying about MediGene AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MediGene AG and related companies.